Similar studies using T cells genetically redirected to express CCR2 and CARs for the treatment of neuroblastoma [17] and malignant mesothelioma [19] also appear to support the idea that the CCR2-CCL2 axis is a rational choice for use in redirected T cell-based anticancer adoptive immunotherapy. This evidence concerns the gene CCL2 and neuroblastoma.